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Abstract
Background: Tobacco dependence management is a multi-component intervention that includes
pharmacological treatments such as Nicotine Substitution Therapy (NST) or bupropion, and
psychological therapy. There are some preliminary reports on topiramate efficacy for tobacco
dependence. The aim of this study is to determine whether topiramate is as effective as the
standard NST treatment for tobacco cessation at 1-year follow-up in patients with depression.
Method/design: Design: A randomised, controlled trial involving two groups, one of which is the
control group consisting of patients on the standard pharmacological treatment for tobacco
cessation (NST) and the other is the intervention group consisting of patients on topiramate as
pharmacological treatment.
Setting: 29 primary care health centres in the city of Zaragoza, Spain.
Sample: 180 patients, aged 18–65 years, diagnosed with major depression, smoke more than 20
cigarettes/day, who have voluntarily asked for tobacco cessation therapy.
Intervention: A multi-component programme for tobacco cessation is offered to all of the patients
in the study. This programme is made up of pharmacological therapy + group cognitive-behavioural
therapy. Pharmacological therapy consists of NST for the control group and topiramate (200 mg/
day) for the intervention group. Psychological therapy is made up of 16 sessions of manualised
group therapy.
Measurements: Cessation will be assessed by patient self-declared abstinence, expired air carbon
monoxide levels, and cotinine levels in saliva. Questionnaires on tobacco dependence, anxiety,
depression, impulsiveness and self-efficacy will be administered. The interviewers will not know
which group the patient belongs to (blind). The assessments will be carried out at baseline, D
(cessation day) -1, D+1, weeks 1, 2, 3, 4, 6, 8, 10 and 13, and months 4, 5, 6, 8, 10 and 12.
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Main variables: Tobacco cessation rates and tobacco dependence.
Analysis: The analysis will be per intent to treat. We will use the general linear models of the SPSS
version 15 statistical package, to analyse the effect of the treatment on the result variable (tobacco
cessation rate).
Discussion: It is necessary to develop new and more effective pharmacological treatments for
tobacco cessation. This randomised clinical trial will determine whether topiramate is effective for
tobacco cessation in patients with depression.
Trial registration: Current Controlled Trials ISRCTN93532081
Background
Tobacco abuse is the main avoidable cause of death and
disability in the world that is unrelated to others. The
World Health Organization (WHO) estimates that 4 mil-
lion persons died of tobacco-related disorders in 2002 [1].
In Spain, the latest available data from the National
Health Survey (Encuesta Nacional de Salud) in 2003 [2]
describe a prevalence of tobacco consumption of 31%,
with a decrease in consumption by males, and a small but
significant increase in consumption by females, mainly in
adolescents and young women. For these reasons tobacco
use is considered a public health problem and its treat-
ment constitutes a challenge for health services.
At present, tobacco dependence management is carried
out in a collaborative way in primary care and specialised
settings by means of treatments that range from minimal
to intensive intervention [3]. In the latter, a multi-compo-
nent cessation intervention is applied by health profes-
sional specialised in tobacco dependence management
[4,5]. The multi-component intervention includes first-
line pharmacological treatments for tobacco such as Nic-
otine Substitution Therapy (NST) or bupropion, and psy-
chological treatments. This intervention obtains a
remission rate of 30–40% at 1-year follow-up [5,6]. As
psychological therapy, cognitive-behavioural interven-
tions, which can be administered on a group or individual
basis, are used with follow-up sessions during the first
year of abstinence. NST is administered by transdermal
patches as basal treatment [7-9], added to nicotine loz-
enges [10] or nicotine chewing gums [11] that are self-
administered occasionally depending on abstinence
symptoms. Bupropion is a noradrenergic and dopaminer-
gic antidepressant used for tobacco dependence because it
acts on nicotinic receptors. It is twice as effective as a pla-
cebo for this treatment [12]. However, in psychiatric
patients it should be used with caution owing to potential
interactions with CYP2D6, an enzyme involved in the
metabolisation of many psychiatric drugs [13].
Topiramate seems to be a new and promising pharmaco-
logical treatment for tobacco. A new antiepileptic drug, it
was originally designed as an oral hypoglycaemic, and
was subsequently approved as an anticonvulsant. It has
increasingly been used in the treatment of numerous psy-
chiatric conditions (binge eating disorders, bulimia ner-
vosa, and alcohol dependence) and it has also been
associated with weight loss, potentially relevant in revers-
ing weight gain induced by psychotropic medications
[14]. Topiramate has demonstrated its efficacy for the
treatment of alcohol dependence in randomised control-
led trials [15]. There are also some preliminary reports of
its effectiveness for the treatment of tobacco dependence,
despite these reports being substudies of other trials on
alcohol dependence [16], uncontrolled studies with small
samples [17] or short-term studies [18].
Recently, a group of smokers have been described as "spe-
cial populations". These are groups with certain character-
istics that require the need for more intensive treatments
to attain tobacco cessation, owing to limitations in the use
of pharmacological treatments (pregnancy) or because
the cessation must be more immediate (patients with
heart disorders or emphysema) [4]. One of these special
populations is psychiatric patients in whom prevalence of
tobacco dependence is higher than in the general popula-
tion (52% vs. 31%) and effectiveness of cessation pro-
grammes are less effective [19]. In persons who smoke,
there is a direct relationship between severity of psychiat-
ric symptoms and tobacco dependence [20]. Specifically,
patients with depression show more likelihood to become
heavy smokers, to have more difficulties in stopping
smoking, and to suffer from more abstinence symptoms
than general population [21]. At present, there are not
enough research studies on the effectiveness of topiramate
for tobacco cessation and, specifically, in psychiatric pop-
ulations such as patients with depression.
Methods/Design
Objectives
The general aim is to determine whether topiramate is at
least as effective as NST in tobacco cessation at 1-year fol-
low-up in patients with depression. The specific aims are
to determine the factors that predict a good response to
topiramate treatment and the possible differences in effec-
tiveness in relation to gender.BMC Family Practice 2008, 9:28 http://www.biomedcentral.com/1471-2296/9/28
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Design
This is a controlled trial with a random allocation of
patients into two alternative branches (see Figure 1):
1. Tobacco cessation standard treatment with NST (con-
trol group) and
2. Tobacco cessation treatment with topiramate (interven-
tion group).
The evaluation of the treatment outcomes will be per-
formed at patient level and they will be assessed individu-
ally.
Setting and study sample
Patients will be recruited from any of the 29 primary
health care centres in the city of Zaragoza (Aragonese
Health Service), Spain. Patients will be recruited by doc-
tors working in these primary care centres until the
required sample is completed, without a quota of patients
assigned for every centre.
Patients considered for inclusion are those aged 18–65
years, able to understand and read Spanish, who fulfil cri-
teria for major depression (DSM-IV criteria), with scores
on the Zung Self-Rating Depression Scale < 60 [22]
(implying minimal to mild depression), who smoke more
than 20 cigarettes/day, fulfil preparation state of change
according to Prochaska & DiClemente [23], voluntarily
ask for a tobacco cessation therapy, and sign informed
consent. Those excluded will be patients with active psy-
chosis and/or treatment with antipsychotic drugs, alcohol
or drug abuse, and pregnancy or lactation.
Flowchart: randomisation, sampling and monitoring of patients Figure 1
Flowchart: randomisation, sampling and monitoring of patients.
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Randomisation, allocation and masking of study groups
Each patient will be allocated to either the intervention or
the control group using a computer-generated random
number sequence. The allocation will be carried out by an
independent person, belonging to REDIAPP (Research
Network on Preventative Activities and Health Promo-
tion), who is not involved in the study. The method used
to implement the random allocation sequence will be a
central telephone. The sequence will be concealed until
interventions are assigned. Patients agree to participate
before the random allocation and without knowing
which treatment they will be allocated to. Pharmacologi-
cal treatment will be administered by a psychiatrist (JGC).
Study personnel conducting psychological intervention
and assessments (NS, AM, AC) will be masked to partici-
pants' treatment conditions.
Intervention
Psychological intervention in both groups
A multi-component programme for tobacco cessation is
offered to all of the patients in the study. This is made up
of pharmacological therapy + group cognitive-behav-
ioural therapy. The group is made up of 7–12 patients
with depression and tobacco dependence, and is led by 2
therapists (a psychologist and a family doctor) trained in
group therapy and tobacco cessation. Each session lasts 90
min., and the structure of every session and the contents
are manualised and based on the standard programmes of
this type [19]. It consists of 16 follow-up sessions: D (ces-
sation day) -1, D +1, weeks 1, 2, 3, 4, 6, 8, 10 and 13, and
months 4, 5, 6, 8, 10 and 12. Patients will be offered a
phone number on which study personnel can solve prob-
lems and answer queries in relation to psychological (NS,
AM) or pharmacological treatment (JGC).
Pharmacological intervention
Intervention group
In this group of patients, topiramate at doses used for the
treatment of addictions (100–200 mg/day) will be admin-
istered [15-17].
Control group (standard treatment)
In this group, NST (nicotine patches) at usual doses (21
mg/day first and second fortnight, 14 mg/day third fort-
night and 7 mg/day fourth and last fortnight), will be
offered.
Pharmacological treatments will be financed by the grant.
It will be administered by a psychiatrist (JGC). Duration
of treatment, in both groups, will be 8 weeks. All patients
will have free use of nicotine gums or lozenges during the
two months of the treatment.
Measurements
The study personnel that carried out the measurements
(NS, AM, AC) will be unaware of which pharmacological
treatment the patients is being administered ("blind").
The follow-up assessments will take place at baseline
(clinical interview), D -1, D + 1, weeks 1, 2, 3, 4, 6, 8, 10
and 13, and months 4, 5, 6, 8, 10 and 12.
Table 1: Study variables
Instrument Assessment area Applied by Time(s) of assessments
Sampling form Age, sex, inclusion/exclusion criteria Family doctor Baseline
Sociodemographic data form Age, sex, marital status, educational 
level, Socio-economic group (28), 
occupation
Research assistant Baseline
MINI psychiatric interview, depression 
and tobacco dependence modules (27)
Psychiatric diagnosis Research psychiatrist Baseline
Zung Self-Rating Depression Scale (22) Severity of depression Research assistant Baseline and possible relapses
State of change (23) State of change Research assistant Baseline
Self-declared abstinence Tobacco abstinence Research assistant Baseline and all follow-up sessions*
Minnesota tobacco abstinence 
symptoms (24)
Tobacco abstinence Research assistant Baseline and all follow-up sessions*
Expired air carbon monoxide levels 
(25)
Tobacco abstinence Research assistant Baseline and all follow-up sessions*
Cotinine levels in saliva Tobacco abstinence Research assistant Baseline and all follow-up sessions*
Fagerström test for Nicotine 
Dependence (29)
Tobacco dependence Research assistant Baseline and many follow-up sessions**
State-Trait Anxiety Inventory (STAI) 
(30)
Anxiety Research assistant Baseline and many follow-up sessions**
Plutchik Impulsivity Scale (31) Impulsivity Research assistant Baseline and many follow-up sessions**
Visual analog scale Efficacy self-perception Research assistant Baseline and many follow-up sessions**
Medical record Pharmacological side-effect events Research assistant Baseline and many follow-up sessions**
*All follow-up sessions: D (cessation day) -1, D + 1, weeks 1, 2, 3, 4, 6, 8, 10 and 13, and months 4, 5, 6, 8, 10 and 12 (16 sessions in total) **Many 
follow-up sessions: weeks 1, 4, 8 and months 4, 6, 8, 10, 12.BMC Family Practice 2008, 9:28 http://www.biomedcentral.com/1471-2296/9/28
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Variables and instruments of measurement (See Table 1)
Main outcome variables
In accordance with the aims of the study, the major out-
come is tobacco cessation in patients with depression. The
diagnosis of tobacco dependence will be made with the
Spanish version of the MINI psychiatric interview sub-
stance dependence module adapted to tobacco [24]. This
modification has been validated on a Spanish population
with adequate psychometric properties [19]. Tobacco
abstinence will be diagnosed by self-declared abstinence,
self-administered Minnesota tobacco abstinence symp-
toms [25], expired air carbon monoxide [26], and coti-
nine in saliva. Tobacco abstinence, according to
majoritarily-accepted criteria [27], has been defined using
2 concepts: 1. Occasional abstinence: In a follow-up visit,
patients affirm that they have been abstinent, their levels
of expired air carbon monoxide < 10 ppm, and cotinine
levels in saliva < 5 ng/ml. Continuous abstinence: As of
the visit at 30 days, patients affirm that they were absti-
nent the month before, expired air carbon monoxide lev-
els < 10 ppm and cotinine levels in saliva < 5 ng/ml.
Tobacco relapse will be diagnosed with the MINI psychi-
atric interview substance dependence module adapted to
tobacco [24].
The diagnosis of depressive disorder will be made with the
Spanish version of the MINI psychiatric interview, depres-
sion module [24], and the severity of the depression with
the Spanish version of the Zung Self-Rating Depression
Scale [22]. Recruitment will only include patients with
depressive disorder and Zung scale scores < 60, which
implies minimal to mild depression [22]. MINI psychiat-
ric interview depression module [24], will be also used as
criteria for depression relapse.
Secondary variables
-The following socio-demographic data will be collected:
sex, age, marital status (single, married/relationship, sep-
arated/divorced, and widowed), education (no studies,
primary, lower secondary, upper secondary, university),
occupation and social class (I, II, IIIN, IIIM, IV and V of
the British Registrar General's Scale) [28].
-Tobacco dependence as measured by the Spanish version
of the Fagerström test for Nicotine Dependence [29].
-Anxiety trait and state as measured by the Spanish version
of the State-Trait Anxiety Inventory (STAI) [30].
-Impulsivity as measured by the Spanish version of the
Plutchik Impulsivity Scale [31].
-Visual analogue scale for efficacy self-perception (range
0–10).
-Pharmacological side-effect events from the medical
record.
Statistical methods
Sample size
To calculate the sample size we consider the tobacco ces-
sation rate at 1 year follow-up as the main outcome varia-
ble. On the basis of published research data [5,6], we
assume that this will be 35% in the control (NST) group,
and we aim to detect a difference of 25% or more between
any of the two groups (control and intervention). Pub-
lished studies place placebo response at 10% [32]. Accept-
ing an alpha risk of 0.05 and a beta risk of < 0.20 in a
bilateral contrast, we would need 90 patients in each
group [33].
Analysis strategy
The analysis will be per intent to treat. First we will com-
pare the intervention group with the control group in
order to verify that there are no significant differences
between the two groups (socio-demographic characteris-
tics, clinical baseline data, etc). We will use the mean
(standard deviation) in the continuous variables and per-
centages in the categorical variables. For comparisons we
will use the Student-t test for continuous variables and the
Chi-squared test for categorical variables. Non-parametric
tests may also be used.
The main variables of the result are the percentage of
patients with tobacco cessation (patient's self-declared
abstinence, expired air carbon monoxide levels, self-
administered Minnesota tobacco abstinence symptoms,
and cotinine levels in saliva), and tobacco dependence
(Fagerström test for Nicotine Dependence scoring) at 1-
year.
Process variables include severity of the depression (Zung
Self-Rating Depression Scale), anxiety trait and state
(STAI), impulsivity (Plutchik Impulsivity Scale), and effi-
cacy self-perception (visual analogue scale).
We will use the general linear models of the SPSS 15 sta-
tistical package, to analyse the effect of the treatment on
the categorical result variables (tobacco cessation rate).
We will use the analyses of linear mixed models to analyse
the effect of the continuous process variables (depression,
anxiety, impulsivity and efficacy).
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of which group they are to be
included in. Before they give their consent, the patients
will be provided with a general overview of the aims and
characteristics of the study and the multi-component
intervention. They will also be informed that they will beBMC Family Practice 2008, 9:28 http://www.biomedcentral.com/1471-2296/9/28
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participating voluntarily, and that they can choose to
withdraw at any time with the guarantee that they will
continue to receive the treatment considered most appro-
priate by their doctor.
The study follows Helsinki Convention norms and poste-
rior modifications and the Declaration of Madrid of the
World Psychiatric Association. The Study Protocol was
approved by the Ethical Review Board of the regional
health authority in February 2007 (ref: FIS PI06/1462).
Forecast execution dates
Initial recruitment of patients: March 2008
Finalisation of patient recruitment: December 2008
Finalisation of patient monitoring period: December
2009
Publication of results: June 2010
Discussion
Effectiveness of multi-component programmes with
standard pharmacological treatments (NST) for tobacco
cessation in the general population is still unsatisfactory,
with cessation rates at 1-year follow-up ranging from 30–
40% [5,6]. These rates are even less successful in special
populations such as psychiatric patients [19]. For these
reasons, it seems necessary to develop new and more
effective pharmacological treatments. One of the most
promising treatments is topiramate because it has demon-
strated effectiveness on tobacco cessation in preliminary
studies [16-18], and it is useful in many psychiatric condi-
tions [14].
The strength of the study is that, to our knowledge, this is
the first randomised, controlled trial of topiramate for
tobacco cessation, with the standard treatment (NST) as
comparator. The psychological intervention of the multi-
component programme is the usual group cognitive-
behavioural therapy used in these programmes [19]. In
addition, the modulator role of some important variables
(such as anxiety, impulsivity, state of change, self-efficacy)
in patients with depression has also been assessed.
A number of potential limitations may be difficulties in
recruitment, due to lack of motivation for tobacco cessa-
tion in psychiatric patients, and the low cessation rate in
this population making it difficult to interpret the results.
The concept of states of change has also been criticised, so
its utility may be doubtful.
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